U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Toxikon Corporation/Labcorp Bedford LLC - 623581 - 10/25/2022
  1. Warning Letters

CLOSEOUT LETTER

Toxikon Corporation/Labcorp Bedford LLC MARCS-CMS 623581 —

Product:
Biologics
Recipient:
Recipient Name
Matthew Renninger, DVM, PhD
Recipient Title
Vice President
Toxikon Corporation/Labcorp Bedford LLC
Toxikon Corporation

15 Wiggins Avenue
Bedford, MA 01730-2314
United States

Issuing Office:
Center for Biologics Evaluation and Research

United States

Dear Dr. Renninger:

The United States Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter CBER-22-001 dated February 10, 2022. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or other applicable law.

Sincerely,
/S/
Melissa J. Mendoza, JD
Acting Director
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research


cc: Anne E. Johnson, Director
FDA ORA-BIMO East

Back to Top